不同硝呋太尔制霉素方案治疗妊娠期阴道炎的疗效及母婴结局观察OA
Efficacy and Maternal-Infant Outcomes of Different Nifuratel Nysfungin Regimens in the Treatment of Vaginitis During Pregnancy
目的:比较硝呋太尔制霉素阴道软胶囊不同治疗方案对妊娠期阴道炎的临床疗效,分析其对孕晚期并发症及新生儿结局的影响,为妊娠期阴道炎的精准用药提供依据.方法:采用随机对照研究设计,纳入2023 年3 月—2025 年3 月于某院妇产科确诊的 122 例孕 20～36 周妊娠期阴道炎患者,根据治疗方案分为调整组(n=61)与标准组(n=61).调整组根据孕周及感染程度调整剂量,标准组仅予标准剂量.比较两组治疗后 7 d 症状缓解率、14 d 病原体清除率及临床治愈率;随访至产后 42 d,比较孕晚期并发症发生及新生儿结局情况的差异.结果:治疗后7 d,调整组总症状缓解率(96.72%)显著高于标准组(75.41%),差异有统计学意义(P<0.05);治疗后 14 d,两组总症状缓解率、病原体总清除率比较,差异均无统计学意义(P>0.05).调整组总治愈率(96.72%)显著高于标准组(85.24%),差异有统计学意义(P<0.05).两组孕晚期并发症总发生率比较,差异无统计学意义(P>0.05).调整组新生儿泌尿系统感染率(0)低于标准组(6.56%),差异有统计学意义(P<0.05).调整组总不良反应发生率(3.28%)低于标准组(13.11%),差异具有统计学意义(P<0.05).结论:基于孕周与感染程度的硝呋太尔制霉素阴道软胶囊个体化剂量调整方案可显著提升妊娠期阴道炎的临床疗效、降低新生儿不良结局发生率,且安全性良好.
OBJECTIVE:To compare the clinical efficacy of different treatment regimens of Nifuratel Nysfungin Vaginal Soft Capsules in the treatment of vaginitis during pregnancy,and to analyze their effects on late-pregnancy complications and neonatal outcomes,so as to provide a basis for the precise medication of vaginitis during pregnancy.METHODS:A randomized controlled trial was conducted.A total of 122 patients with vaginitis during pregnancy at 20-36 weeks of gestation,diagnosed in the department of obstetrics and gynecology of our hospital from March 2023 to March 2025,were enrolled and divided into an adjustment group(n=61)and standard group(n=61)according to the treatment regimens.The adjustment group received adjusted dosages based on gestational weeks and the degree of infection,while the standard group received only the standard dosage.The total symptom relief rate 7 days after treatment,and the total pathogen clearance rate and clinical cure rate 14 days after treatment were compared between the two groups.All patients were followed up until 42 days after delivery,and the differences in the incidence of late-pregnancy complications and neonatal outcomes were compared between the two groups.RESULTS:7 days after treatment,the total symptom relief rate in the adjustment group(96.72%)was significantly higher than that in the standard group(75.41%),with statistically significant difference(P<0.05).14 days after treatment,there were no statistically significant differences in the total symptom relief rate or total pathogen clearance rate between the two groups(P>0.05).The total clinical cure rate in the adjustment group(96.72%)was significantly higher than that in the standard group(85.24%),with statistically significant difference(P<0.05).There was no statistically significant difference in the total incidence of late-pregnancy complications between the two groups(P>0.05).The incidence of neonatal urinary tract infection in the adjustment group(0)was lower than that in the standard group(6.56%),with statistically significant difference(P<0.05).The total incidence of adverse reactions in the adjustment group(3.28%)was lower than that in the standard group(13.11%),with statistically significant difference(P<0.05).CONCLUSIONS:The individualized dosage adjustment regimen of Nifuratel Nysfungin Vaginal Soft Capsules based on gestational weeks and the degree of infection can significantly improve the clinical efficacy in the treatment of vaginitis during pregnancy,reduce the incidence of adverse neonatal outcomes,with a favorable safety profile.
王娟;陈剑;闫洁;赵永丽;李丰玲
商洛市中心医院妇科,陕西 商洛 726000商洛市中心医院新生儿科,陕西 商洛 726000商洛市中心医院产科,陕西 商洛 726000商洛市中心医院妇科,陕西 商洛 726000商洛市中心医院新生儿科,陕西 商洛 726000
医药卫生
妊娠期阴道炎硝呋太尔制霉素阴道软胶囊不同治疗方案母婴结局
Vaginitis during pregnancyNifuratel Nysfungin Vaginal Soft CapsulesDifferent treatment regimensMaternal-infant outcomes
《中国医院用药评价与分析》 2026 (9)
1054-1058,5
陕西省卫生健康科研基金项目(No.2023D042)
评论